Radiopharma AAA refiles for up to $75M IPO; Sterigenics does $15M expansion;

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

> Radiopharmaceutical Dx player Advanced Accelerator Applications has refiled for an IPO--with plans to raise up to $75 million. It had previously filed for up to $100 million in November 2014. More

> Medical device sterilization company Sterigenics, which is backed by Warburg Pincus and GTCR, will spend $15 million so expand its capacity at an Arkansas facility. More

> PKA SoftTouch has started a $100K crowdfunding campaign on Indiegogo to back clinical testing for its insulin microneedle that offers a "virtually pain free" option. More

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

> XenoPort hits reset after a psoriasis setback, cutting jobs and bailing on R&D. Report

> Regeneron inks a $325M deal, selling Asian rights to a pain treatment. Story

> Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug. Article

Pharma News

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

> Novartis targets Amgen's Enbrel with second biosimilar app. Story

> Ackman's fund takes a beating on Valeant pricing worries. Item

> FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.